|
- Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer
Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell
- Tarlatamab - Wikipedia
Tarlatamab, sold under the brand name Imdelltra, is an anti-cancer medication used for the treatment of extensive-stage small cell lung cancer [5] It is a bispecific T-cell engager that binds delta-like ligand 3 and CD3
- Tarlatamab for the Treatment of DLL3-Expressing Stage III or IV . . .
Tarlatamab is approved for treatment of patients with extensive stage small cell lung cancer, and may be effective at treating patients with neuroendocrine neoplasms or other solid tumors that express the DLL3 protein
- FDA grants accelerated approval to tarlatamab-dlle for lung cancer
On May 16, 2024, the Food and Drug Administration granted accelerated approval to tarlatamab-dlle (Imdelltra, Amgen, Inc ) for extensive stage small cell lung cancer (ES-SCLC) with disease
- Practical management of adverse events in patients receiving tarlatamab . . .
Tarlatamab received accelerated approval from the US Food and Drug Administration for the treatment of patients with previously treated small cell lung cancer This review summarizes the safety profile of tarlatamab and outlines the strategies used for the management of common adverse events encountered during the DeLLphi‐301 trial INTRODUCTION
- Tarlatamab (Imdelltra): Uses in Cancer, Side Effects, Dosages . . .
Tarlatamab, marketed as Imdelltra, is a bispecific T-cell engager (BiTE®) antibody that harnesses the body’s immune system to fight small cell lung cancer (SCLC) and other DLL3-expressing neuroendocrine tumors
- A phase 2 basket trial of tarlatamab in patients with advanced DLL3 . . .
Tarlatamab is a bispecific T cell engager that binds to DLL3 and CD3 to promote T cell killing of DLL3-expressing cells Prior studies of tarlatamab have demonstrated encouraging antitumor activity and manageable toxicity in patients with small cell lung cancer (SCLC; DeLLphi-301) and neuroendocrine prostate cancer (NEPC; DeLLpro-300)
- Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer . . . - PubMed
Background: Tarlatamab, a bispecific T-cell engager, has shown promising results in previously treated small cell lung cancer (SCLC) patients in the DeLLphi-300 and DeLLphi-301 trials However, reports on outcomes in more diverse, real-world patient populations are limited
|
|
|